Everolimus-eluting stent curbs thrombosis, mortality risk in diabetes

11/29/2012 | Healio

Diabetes patients who were implanted with a second-generation everolimus-eluting stent showed lower stent thrombosis rates and all-cause mortality compared with those who had first-generation sirolimus-eluting and paclitaxel-eluting stents, a study indicated. The results appear in the Journal of the American College of Cardiology: Cardiovascular Interventions.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC